Literature DB >> 1696358

Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations.

A S Nadel1, J K Green, L B Holmes, F D Frigoletto, B R Benacerraf.   

Abstract

BACKGROUND: Recent improvements in the accuracy of sonographic diagnosis of neural-tube and ventral-wall defects have raised a question about the wisdom of routinely offering amniocentesis to women who have elevated levels of maternal serum alpha-fetoprotein with a structurally normal fetus as determined by ultrasonography.
METHODS: We reviewed the ultrasound findings in 51 consecutive fetuses with spina bifida, encephalocele, gastroschisis, or omphalocele that were delivered or aborted at a single hospital, to estimate the sensitivity of ultrasonography for these diagnoses. In all cases, the mothers had undergone prenatal sonography at one facility between 16 and 24 weeks after the last menstrual period. We used these data to calculate the probability of an affected fetus in a women with a given level of maternal serum alpha-fetoprotein and a normal sonogram.
RESULTS: These four types of anomalies were correctly identified in all 51 cases, yielding a sensitivity of 100 percent (95 percent confidence interval, 94 to 100 percent). Using the lower limit of this confidence interval, we calculated that the probability of an affected fetus ranges from 0.01 to 0.15 percent for maternal serum alpha-fetoprotein levels ranging from 2.0 to 3.5 times the median, respectively.
CONCLUSIONS: This level of risk is less than the reported risk of abortion due to amniocentesis and may lead some women with elevated levels of alpha-fetoprotein to decide not to proceed with amniocentesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696358     DOI: 10.1056/NEJM199008303230901

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  7 in total

Review 1.  Prenatal diagnosis of spina bifida: from intracranial translucency to intrauterine surgery.

Authors:  Waldo Sepulveda; Amy E Wong; Francisco Sepulveda; Juan L Alcalde; Juan C Devoto; Felipe Otayza
Journal:  Childs Nerv Syst       Date:  2017-06-07       Impact factor: 1.475

2.  Update and Review: Maternal Serum Screening.

Authors:  K E Ormond
Journal:  J Genet Couns       Date:  1997-12       Impact factor: 2.537

Review 3.  Fetal ultrasonography.

Authors:  S H Garmel; M E D'Alton
Journal:  West J Med       Date:  1993-09

Review 4.  Maternal serum screening for neural tube defects and fetal chromosome abnormalities.

Authors:  N C Rose; M T Mennuti
Journal:  West J Med       Date:  1993-09

5.  Periodic health examination, 1994 update: 3. Primary and secondary prevention of neural tube defects. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1994-07-15       Impact factor: 8.262

6.  Maternal serum screening.

Authors:  J C Carroll
Journal:  Can Fam Physician       Date:  1994-10       Impact factor: 3.275

Review 7.  Fetal surgery for open spina bifida.

Authors:  Adalina Sacco; Fred Ushakov; Dominic Thompson; Donald Peebles; Pranav Pandya; Paolo De Coppi; Ruwan Wimalasundera; George Attilakos; Anna Louise David; Jan Deprest
Journal:  Obstet Gynaecol       Date:  2019-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.